Trulicity Injection Recalled Due to Temperature Exposure During Shipment
A batch of Trulicity (dulaglutide) injection was recalled due to temperature exposure during distribution in New Mexico. The product was exposed to temperatures outside its labeled storage requirements due to inclement weather.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall meets the 'High' severity criterion as a risk-of-harm pharmaceutical product with no reported illnesses, injuries, or deaths. Per the severity rubric, recalls with theoretical hazards and no reported patient harm are limited to a maximum of High.
Plain-English summary
Cardinal Health Inc. is recalling a batch of Trulicity (dulaglutide) injection due to temperature exposure. The affected product is Trulicity injection, 1.5 mg/0.5 mL, supplied as 4 single-dose pens per package, with lot number D482749A and expiration date of 10/15/2023.
The product was exposed to temperatures outside the manufacturer's labeled storage conditions due to inclement weather during distribution. This recall affects products distributed in New Mexico only.
Patients who have received this medication should contact their healthcare provider or pharmacist for guidance.
The recalled product
- Product
- Trulicity (dulaglutide) injection, 1.5 mg/0.5mL once weekly, 4 Single-Dose Pens, Rx only, Eli Lilly and Company, Indianapolis, IN 46285, NDC 00002-1434-80
- Manufacturer
- Cardinal Health Inc.
- Category
- Drug — Injectable Medication
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: D482749A
- Exp: 10/15/2023.
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 3 recalled by Cardinal Health Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Cardinal Health Inc.
See all →- HighEnoxaparin syringe bags recalled after being labeled with the wrong strength
FDA (Drugs) · 2025-09-03
- ModerateXolair auto-injectors exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateRecombinate antihemophilic factor vials exposed to temperatures outside labeled storage
FDA (Drugs) · 2025-08-13
- ModerateXolair 75 mg syringes exposed to temperatures outside labeled storage requirements
FDA (Drugs) · 2025-08-13
- ModerateWegovy injection recalled due to temperature exposure during shipping
FDA (Drugs) · 2025-05-07
Same hazard · temperature abuse
See all →- SevereKayem Foods Recalls Ready-to-Eat Meat and Poultry Due to Temperature Abuse
USDA FSIS · 2026-10-17
- ModerateZoladex Goserelin Implant Recalled Due to Temperature Abuse
FDA (Drugs) · 2026-10-07
- ModerateGemcitabine Injection Recalled Due to Temperature Storage Abuse
FDA (Drugs) · 2026-07-08
- ModerateChristopher Ranch peeled garlic recalled over Clostridium botulinum contamination risk
FDA (Food) · 2026-05-13
- ModerateGarland Fresh peeled garlic recalled over Clostridium botulinum contamination risk
FDA (Food) · 2026-05-13
Similar recalls
- SevereTrulicity autoinjector pens recalled for incorrect strength labeling
FDA (Drugs) · 2021-09-01
- SevereNovo Nordisk Recalls Xultophy 100/3.6 Due to Temperature Abuse
FDA (Drugs) · 2021-04-21
- ModerateNucala Injection Recalled for Temperature Abuse During Storage and Shipping
FDA (Drugs) · 2019-10-02
- ModerateCardinal Health Recalls Ubrelvy Tablets Due to Temperature Excursions
FDA (Drugs) · 2021-06-02
- SevereCardinal Health Recalls Levofloxacin Injection Due to Temperature Excursions
FDA (Drugs) · 2021-06-02
- ModerateCardinal Health Recalls Orilissa Tablets Due to Temperature Excursions
FDA (Drugs) · 2021-06-02